Institute of Ophthalmology, University College London, London, UK.
Moorfields Eye Hospitals United Arab Emirates (UAE), Dubai, UAE.
Am J Med Genet C Semin Med Genet. 2020 Sep;184(3):762-772. doi: 10.1002/ajmg.c.31824. Epub 2020 Aug 11.
Genetic eye diseases are phenotypically and genetically heterogeneous, affecting 1 in 1,000 people worldwide. This prevalence can increase in populations where endogamy is a social preference, such as in Arab populations. A retrospective consecutive cohort of 91 patients from 74 unrelated families affected with non-syndromic and syndromic inherited eye disease presenting to the ocular genetics service at Moorfields Eye Hospitals United Arab Emirates (UAE) between 2017 and 2019, underwent clinically accredited genetic testing using targeted gene panels. The mean ± SD age of probands was 27.4 ± 16.2 years, and 45% were female (41/91). The UAE has a diverse and dynamic population, and the main ethnicity of families in this cohort was 74% Arab (n = 55), 8% Indian (n = 6) and 7% Pakistani (n = 5). Fifty-six families (90.3%) were genetically solved, with 69 disease-causing variants in 40 genes. Fourteen novel variants were detected with large deletions in CDHR1 and TTLL5, a multiexon (1-8) duplication in TEAD1 and 11 single nucleotides variants in 9 further genes. ABCA4-retinopathy was the most frequent cause accounting for 21% of cases, with the confirmed UAE founder mutation c.5882G>A p.(Gly1961Glu)/c.2570T>C p.(Leu857Pro) in 25%. High diagnostic yield for UAE patients can guide prognosis, family decision-making, access to clinical trials and approved treatments.
遗传性眼病在表型和遗传上具有异质性,影响全球每 1000 人中的 1 人。这种患病率在近亲结婚是社会偏好的人群中会增加,如阿拉伯人群。2017 年至 2019 年间,91 名来自 74 个无血缘关系家庭的患有非综合征性和综合征性遗传性眼病的患者在阿联酋迪拜莫尔菲尔德眼科医院眼遗传科接受了临床认可的靶向基因panel 基因检测,这是一项回顾性连续队列研究。先证者的平均年龄为 27.4±16.2 岁,其中 45%为女性(41/91)。阿联酋拥有多元化和充满活力的人口,该队列中家庭的主要民族是 74%的阿拉伯人(n=55),8%的印度人(n=6)和 7%的巴基斯坦人(n=5)。56 个家庭(90.3%)得到了基因解答,在 40 个基因中发现了 69 个致病变异。在 CDHR1 和 TTLL5 中检测到 4 个新的大片段缺失变异,TEAD1 中存在一个多外显子(1-8)重复,9 个进一步的基因中存在 11 个单核苷酸变异。ABCA4-视网膜病变是最常见的病因,占 21%,其中确认的阿联酋创始人突变 c.5882G>A p.(Gly1961Glu)/c.2570T>C p.(Leu857Pro)在 25%的病例中。对阿联酋患者进行高诊断率可以指导预后、家庭决策、获得临床试验和批准的治疗方法。